# Absci Corporation (ABSI) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ABSI
## Company Profile
- Ticker: ABSI
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 10.16 USD
- Market cap: 989997105.5999999 USD
- Last updated: 2026-10-09
## Business Overview
### AI-Enabled Biologic Design
Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models.
### ABS-201
ABS-201 is a long-acting antibody against the prolactin receptor. Its pharmacokinetic profile is intended to support only a few injections over a six-month treatment period.
### Pattern Hair Loss
The Phase 1/2a HEADLINE study evaluates ABS-201 as a potentially durable treatment for male and female pattern hair loss through a mechanism distinct from existing therapies.
### Endometriosis
Absci is also advancing ABS-201 as a potential non-sex-steroid, disease-modifying treatment that could address both pain and lesion growth in endometriosis.
### Prolactin-Focused Pipeline
ABS-202 is a second anti-prolactin-receptor antibody in preclinical development for an undisclosed inflammatory and immunologic indication, extending the company's internal prolactin biology franchise.
## Why The Stock Is Moving

As of Oct 9, 2026, ABSI closed up 13.6% at $10.16. No new same-company headline was identified in the current news window.

## Future Catalysts

- Interim proof-of-concept data from the HEADLINE study of ABS-201 in pattern hair loss in the second half of 2026.
- Initiation of a Phase 2 study of ABS-201 in endometriosis in the fourth quarter of 2026.
- Full proof-of-concept data from HEADLINE in early 2027.
- Potential proof-of-concept data from the Phase 2 endometriosis study in the second half of 2027.

## Recent News
- 2026-09-24 12:00 EST — [Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis](https://biopharmsignal.com/news/ABSI/absci-announces-preliminary-details-for-phase-2-storyline-trial-of-ai-designed-a-54049d48) — Source: Absci Corporation
- 2026-09-01 12:00 EST — [Absci to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ABSI/absci-to-participate-in-upcoming-investor-conferences-52fc7dab) — Source: Absci Corporation
- 2026-08-11 20:05 EST — [Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/ABSI/absci-reports-business-updates-and-second-quarter-2026-financial-and-operating-r-8f88417e) — Source: Absci Corporation
- 2026-07-14 20:05 EST — [Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026](https://biopharmsignal.com/news/ABSI/absci-to-report-business-updates-and-second-quarter-2026-financial-and-operating-a4348c21) — Source: Absci Corporation
- 2026-06-24 10:35 EST — [Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors](https://biopharmsignal.com/news/ABSI/absci-announces-pricing-of-100-million-underwritten-offering-with-leading-strate-23f03cff) — Source: Absci Corporation